Experience of etanercept treatment in juvenile ankylosing spondyloarthritis

Abstract

A history case of severe juvenile ankylosing spondyloarthritis, characterized by rapid development of asymmetric polyarticular syndrome, sacroiliitis, patient’s incapacity and low quality of his and his family life, is discussed in this article. The activity of pathological process was managed to be suppressed due to successful usage of soluble tumor necrosis factor α receptor — etanercept. As a result of treatment the recurrence of articular syndrome was arrested, the function in almost all of the involved joints was recovered, laboratory markers of inflammatory activity decreased. Non-active stage of the disease was established in 12 weeks of etanercept treatment, remission — in 9 months.

Keywords

• children
• juvenile ankylosing spondyloarthritis
• etanercept
• treatment